Attached files
| file | filename |
|---|---|
| 8-K - Emergent BioSolutions Inc. | form8-k.htm |
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2011
ROCKVILLE, MD, March 8, 2012—Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the fourth quarter and full year ended December 31, 2011.
Total revenues for 2011 were $273.4 million as compared to $286.2 million in 2010, and net income for 2011 was $23.0 million, or $0.65 per basic share, as compared to $51.7 million, or $1.63 per basic share, in 2010.
For the fourth quarter 2011, total revenues were $107.9 million as compared to $103.2 million in 2010, and net income was $28.7 million, or $0.80 per basic share, as compared to $26.2 million, or $0.78 per basic share, in 2010.
R. Don Elsey, chief financial officer of Emergent BioSolutions, commented, “Throughout 2011, we continued to execute on our operating plan. We manufactured and delivered doses of BioThrax into the SNS, we made progress on Building 55 scale up, we secured a multi-year contract to supply BioThrax to the SNS through September 2016 valued at up to $1.25 billion, and we advanced the development of our clinical stage programs targeting infectious disease, autoimmune and inflammatory disorders and oncology. We look to build on this performance throughout 2012.”
2011 Key Operational Accomplishments
|
·
|
Secured a new CDC procurement contract, valued at up to $1.25 billion, to supply 44.75 million doses of BioThrax® (Anthrax Vaccine Adsorbed) to the SNS through September 2016;
|
|
·
|
Completed multiple engineering runs in Building 55 under a multi-year BARDA development contract, valued at up to $107.0 million, to fund qualification, validation and licensure of the manufacture of BioThrax in Building 55 at large-scale;
|
|
·
|
Completed dosing in a Phase 1 safety study for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant) and a Phase 1 safety study for ThravixaTM (Fully Human Anthrax Monoclonal Antibody);
|
|
·
|
Completed dosing in a Phase 2b infant efficacy study for MVA85A (Recombinant Tuberculosis Vaccine);
|
|
·
|
Initiated enrollment in a Phase 2b efficacy study for MVA85A in HIV-infected adults;
|
|
·
|
Completed enrollment in a Phase 1b combination study for TRU-016 in relapsed CLL;
|
|
·
|
Initiated dosing in the Phase 2 portion of the combination study for TRU-016 in relapsed CLL;
|
|
·
|
Completed enrollment in a Phase 1b combination study of TRU-016 in NHL;
|
|
·
|
Completed enrollment in a Phase 2 dose finding study of SBI-087 in RA (by Pfizer); and
|
|
·
|
Completed dosing in a Phase 1 safety and PK study of SBI-087 in SLE (by Pfizer).
|
2011 Key Financial Results
Product Sales
For the full twelve months of 2011, product sales were $202.4 million, a decrease of $49.0 million, or 19 percent, from $251.4 million in the comparable period of 2010, primarily due to a 21 percent decrease in the number of doses of BioThrax delivered due to the redeployment of potency testing capacity from BioThrax release testing to qualification of replacement reference standards and other development testing during the first quarter of 2011, coupled with decreased production yield in the period in which the doses were produced.
For 4Q 2011, product sales were $81.7 million, a decrease of $7.7 million, or 9 percent, from $89.4 million in 4Q 2010, due to a 6 percent decrease in the number of doses of BioThrax delivered due primarily to decreased production yield in the period in which the doses were produced.
Contracts and Grants Revenues
For the full twelve months of 2011, contracts and grants revenue was $71.0 million, an increase of $36.2 million, or 104 percent, from $34.8 million in the comparable period of 2010. For 4Q 2011, contracts and grants revenue was $26.3 million, an increase of $12.4 million, or 90 percent, from $13.9 million in 4Q 2010. The increase in contracts and grants revenue was primarily due to revenues from our contract with BARDA for large-scale manufacturing for BioThrax and our collaborations with Abbott and Pfizer, along with increased activity and associated revenue from our development contracts with NIAID and BARDA for NuThrax and PreviThraxTM.
Cost of Product Sales
For the full twelve months of 2011, cost of product sales was $42.2 million, a decrease of $4.9 million, or 10 percent, from $47.1 million in the comparable period of 2010. The decrease in 2011 was attributable to the reduced number of doses of BioThrax delivered, partially offset by an increase in the cost per dose sold associated with decreased production yield in the period in which the doses were produced.
For 4Q 2011, cost of product sales was $14.3 million, a decrease of $2.7 million, or 16 percent, from $17.0 million in 4Q 2010. The decrease was attributable to the reduced number of doses of BioThrax delivered, coupled with cost savings associated with a shorter manufacturing shut down in 2011 as compared to 2010.
Research and Development
For the full twelve months of 2011, research and development expenses were $124.8 million, an increase of $35.5 million, or 40 percent, from $89.3 million in the comparable period of 2010. This increase primarily reflects higher contract service and personnel-related costs, and includes increased expenses of $30.0 million for product candidates and technology platform development activities that are categorized in the biosciences segment, increased expenses of $4.0 million categorized in the biodefense segment, and increased expenses of $1.6 million in other research and development. For 2011 and 2010, net R&D expenses were $47.0 million and $50.0 million, respectively. Net R&D expense is calculated as research and development expenses less development contract and grant reimbursements and the net loss attributable to noncontrolling interests.
For 4Q 2011, research and development expenses were $29.4 million, a decrease of $0.2 million, or 1 percent, from $29.6 million in 4Q 2010. For 4Q 2011 and 2010, net R&D expenses were $1.3 million and $13.4 million, respectively.
Selling, General and Administrative
For the full twelve months of 2011, general and administrative expenses were $74.3 million, a decrease of $1.9 million, or 3 percent, from $76.2 million in the comparable period of 2010. This decrease is primarily due to decreased spending related to professional services partially offset by increased personnel costs.
For 4Q 2011, selling, general and administrative expenses were $18.3 million, a decrease of $3.4 million, or 16 percent, from $21.7 million in 4Q 2010. This decrease is primarily due to costs incurred in the restructuring of the Company’s UK operations in 4Q 2010.
Financial Condition and Liquidity
Cash and cash equivalents combined with investments at December 31, 2011 was $145.9 million compared to $171.0 million at December 31, 2010. Additionally, at December 31, 2011, the accounts receivable balance was $74.2 million, as compared to $39.3 million at December 31, 2010. The accounts receivable balance for both periods is comprised primarily of unpaid amounts due related to shipments of BioThrax accepted by the US government.
2012 Forecast
For 2012, the Company is reaffirming its financial forecast of total revenue of $280 to $300 million, split between product sales of $220 to $230 million and contracts and grants revenue of $60 to $70 million. The Company also forecasts net income of $15 to $25 million.
2012 total revenue is expected to be driven by, among other things:
|
·
|
Increased dose deliveries of BioThrax under the current multi-year procurement contract with CDC; and,
|
|
·
|
Contracts and grants revenue based on continuing work under existing, multi-year development contracts associated primarily with the Company’s BioDefense Division programs.
|
For the first quarter of 2012, the company anticipates total revenues of $40 to $50 million.
Conference Call and Webcast
Company management will host a conference call at 5:00 pm Eastern on March 8, 2012 to discuss these financial results. The conference call will be accessible by dialing 888/680-0878 or 617/213-4855 (international) and providing passcode 35663572. A webcast of the conference call will be accessible from the Company’s website at www.emergentbiosolutions.com, under “Investors”. A replay of the conference call will be accessible, approximately two hours following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using passcode 57332722. The replay will be available through March 22, 2012. The webcast will be archived on the Company’s website, www.emergentbiosolutions.com, under “Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent’s marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2012, and our expected revenue for 1Q 2012, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. Such statements are based upon the current beliefs and expectations of management that are subject to risks, uncertainties and other important factors that could cause the Company’s actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax® procurement; our ability to obtain new BioThrax® sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax®; our ability to perform under our current development contracts with the U.S. government; our plans to expand our manufacturing facilities and capabilities, including our ability to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® in our large-scale vaccine manufacturing facility in Lansing, Michigan; the rate and degree of market acceptance of our products and product candidates; the success of preclinical studies and clinical trials of our product candidates and post-approval clinical utility of our products; the potential benefits of our existing collaborations and our ability to selectively enter into additional collaborative arrangements; the extent to which our licensing and acquisition activities are complementary to the Company or whether anticipated synergies and benefits are realized within expected time periods; our ability to identify and acquire or in-license products and product candidates that satisfy our selection criteria; ongoing and planned development programs, preclinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 and subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
###
Investor Contact
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com
Financial Statements Follow
|
Emergent BioSolutions Inc. and Subsidiaries
|
||||||||
|
Consolidated Balance Sheets
|
||||||||
|
(in thousands, except share and per share data)
|
||||||||
|
December 31,
|
December 31,
|
|||||||
|
2011
|
2010
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 143,901 | $ | 169,019 | ||||
|
Investments
|
1,966 | 2,029 | ||||||
|
Accounts receivable
|
74,153 | 39,326 | ||||||
|
Inventories
|
14,661 | 12,722 | ||||||
|
Deferred tax assets, net
|
1,735 | 2,638 | ||||||
|
Income tax receivable, net
|
9,506 | 8,728 | ||||||
|
Restricted cash
|
220 | 217 | ||||||
|
Prepaid expenses and other current assets
|
8,276 | 8,814 | ||||||
|
Total current assets
|
254,418 | 243,493 | ||||||
|
Property, plant and equipment, net
|
208,973 | 152,701 | ||||||
|
In-process research and development
|
51,400 | 51,400 | ||||||
|
Goodwill
|
5,502 | 5,029 | ||||||
|
Assets held for sale
|
11,765 | 12,741 | ||||||
|
Deferred tax assets, net
|
13,999 | 33,757 | ||||||
|
Other assets
|
807 | 1,198 | ||||||
|
Total assets
|
$ | 546,864 | $ | 500,319 | ||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$ | 40,530 | $ | 25,409 | ||||
|
Accrued expenses and other current liabilities
|
1,170 | 1,309 | ||||||
|
Accrued compensation
|
20,884 | 23,975 | ||||||
|
Contingent value rights, current portion
|
1,748 | - | ||||||
|
Long-term indebtedness, current portion
|
5,360 | 17,187 | ||||||
|
Deferred revenue, current portion
|
1,362 | 7,839 | ||||||
|
Total current liabilities
|
71,054 | 75,719 | ||||||
|
Contingent value rights, net of current portion
|
3,005 | 14,532 | ||||||
|
Long-term indebtedness, net of current portion
|
54,094 | 30,239 | ||||||
|
Deferred revenue, net of current portion
|
- | 4,386 | ||||||
|
Other liabilities
|
1,984 | 1,882 | ||||||
|
Total liabilities
|
130,137 | 126,758 | ||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2011 and 2010, respectively
|
- | - | ||||||
|
Common stock, $0.001 par value; 100,000,000 shares authorized, 36,002,698 and 35,011,423 shares issued and outstanding at December 31, 2011 and 2010, respectively
|
36 | 35 | ||||||
|
Additional paid-in-capital
|
220,654 | 197,689 | ||||||
|
Accumulated other comprehensive loss
|
(3,313 | ) | (2,110 | ) | ||||
|
Retained earnings
|
196,869 | 173,850 | ||||||
|
Total Emergent BioSolutions Inc. stockholders’ equity
|
414,246 | 369,464 | ||||||
|
Noncontrolling interest in subsidiaries
|
2,481 | 4,097 | ||||||
|
Total stockholders’ equity
|
416,727 | 373,561 | ||||||
|
Total liabilities and stockholders’ equity
|
$ | 546,864 | $ | 500,319 | ||||
|
Emergent BioSolutions Inc. and Subsidiaries
|
||||||||
|
Consolidated Statements of Operations
|
||||||||
|
(in thousands, except share and per share data)
|
||||||||
|
Twelve Months Ended
|
||||||||
|
December 31,
|
||||||||
|
2011
|
2010
|
|||||||
|
Revenues:
|
||||||||
|
Product sales
|
$ | 202,409 | $ | 251,381 | ||||
|
Contracts and grants
|
70,975 | 34,790 | ||||||
|
Total revenues
|
273,384 | 286,171 | ||||||
|
Operating expenses:
|
||||||||
|
Cost of product sales
|
42,171 | 47,114 | ||||||
|
Research and development
|
124,832 | 89,295 | ||||||
|
Selling, general and administrative
|
74,282 | 76,205 | ||||||
|
Income from operations
|
32,099 | 73,557 | ||||||
|
Other income (expense):
|
||||||||
|
Interest income
|
105 | 832 | ||||||
|
Interest expense
|
- | - | ||||||
|
Other income (expense), net
|
(261 | ) | (1,023 | ) | ||||
|
Total other income (expense)
|
(156 | ) | (191 | ) | ||||
|
Income before provision for income taxes
|
31,943 | 73,366 | ||||||
|
Provision for income taxes
|
15,830 | 26,182 | ||||||
|
Net income
|
16,113 | 47,184 | ||||||
|
Net loss attributable to noncontrolling interest
|
6,906 | 4,514 | ||||||
|
Net income attributable to Emergent BioSolutions Inc.
|
$ | 23,019 | $ | 51,698 | ||||
|
Earnings per share - basic
|
$ | 0.65 | $ | 1.63 | ||||
|
Earnings per share - diluted
|
$ | 0.64 | $ | 1.59 | ||||
|
Weighted-average number of shares - basic
|
35,658,907 | 31,782,286 | ||||||
|
Weighted-average number of shares - diluted
|
36,206,052 | 32,539,500 | ||||||
|
Emergent BioSolutions Inc. and Subsidiaries
|
||||||||
|
Consolidated Statements of Operations
|
||||||||
|
(in thousands, except share and per share data)
|
||||||||
|
Three Months Ended
|
||||||||
|
December 31,
|
||||||||
|
2011
|
2010
|
|||||||
|
(Unaudited)
|
||||||||
|
Revenues:
|
||||||||
|
Product sales
|
$ | 81,670 | $ | 89,390 | ||||
|
Contracts and grants
|
26,278 | 13,857 | ||||||
|
Total revenues
|
107,948 | 103,247 | ||||||
|
Operating expenses:
|
||||||||
|
Cost of product sales
|
14,328 | 16,998 | ||||||
|
Research and development
|
29,376 | 29,615 | ||||||
|
Selling, general and administrative
|
18,254 | 21,671 | ||||||
|
Income from operations
|
45,990 | 34,963 | ||||||
|
Other income (expense):
|
||||||||
|
Interest income
|
24 | 31 | ||||||
|
Interest expense
|
- | - | ||||||
|
Other income (expense), net
|
(252 | ) | (12 | ) | ||||
|
Total other income (expense)
|
(228 | ) | 19 | |||||
|
Income before provision for income taxes
|
45,762 | 34,982 | ||||||
|
Provision for income taxes
|
18,862 | 11,094 | ||||||
|
Net income
|
26,900 | 23,888 | ||||||
|
Net loss attributable to noncontrolling interest
|
1,757 | 2,359 | ||||||
|
Net income attributable to Emergent BioSolutions Inc.
|
$ | 28,657 | $ | 26,247 | ||||
|
Earnings per share - basic
|
$ | 0.80 | $ | 0.78 | ||||
|
Earnings per share - diluted
|
$ | 0.78 | $ | 0.76 | ||||
|
Weighted-average number of shares - basic
|
35,972,320 | 33,822,874 | ||||||
|
Weighted-average number of shares - diluted
|
36,520,245 | 34,684,876 | ||||||
|
Emergent BioSolutions Inc. and Subsidiaries
|
||||||||
|
Consolidated Statements of Cash Flows
|
||||||||
|
(in thousands)
|
||||||||
|
Twelve Months Ended
|
||||||||
|
December 31,
|
||||||||
|
2011
|
2010
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net income
|
$ | 16,113 | $ | 47,184 | ||||
|
Adjustments to reconcile to net cash provided by operating activities:
|
||||||||
|
Stock-based compensation expense
|
10,739 | 7,063 | ||||||
|
Depreciation and amortization
|
9,355 | 5,990 | ||||||
|
Deferred income taxes
|
20,188 | 9,229 | ||||||
|
Non-cash development expenses from joint venture
|
5,290 | 5,995 | ||||||
|
Impairment of long-lived assets
|
976 | 1,218 | ||||||
|
Change in fair value of contingent value rights
|
221 | - | ||||||
|
Provision for impairment of accrued interest on note receivable
|
- | 1,032 | ||||||
|
Excess tax benefits from stock-based compensation
|
(2,200 | ) | (1,700 | ) | ||||
|
Other
|
392 | (38 | ) | |||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
(34,873 | ) | 19,094 | |||||
|
Inventories
|
(1,939 | ) | 799 | |||||
|
Income taxes
|
1,422 | (4,454 | ) | |||||
|
Prepaid expenses and other assets
|
660 | (764 | ) | |||||
|
Accounts payable
|
2,510 | 3,392 | ||||||
|
Accrued expenses and other liabilities
|
(95 | ) | (447 | ) | ||||
|
Accrued compensation
|
(3,303 | ) | 6,175 | |||||
|
Deferred revenue
|
(10,863 | ) | (838 | ) | ||||
|
Net cash provided by operating activities
|
14,593 | 98,930 | ||||||
|
Cash flows from investing activities:
|
||||||||
|
Purchases of property, plant and equipment
|
(54,026 | ) | (22,101 | ) | ||||
|
Proceeds from maturity of investments
|
4,250 | 6,518 | ||||||
|
Purchase of investments
|
(4,187 | ) | - | |||||
|
Acquisition of Trubion Pharmaceuticals, Inc., net of cash acquired
|
- | (17,873 | ) | |||||
|
Repayment of note receivable
|
- | 10,000 | ||||||
|
Net cash used in investing activities
|
(53,963 | ) | (23,456 | ) | ||||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from borrowings on long-term indebtedness and line of credit
|
27,522 | 15,000 | ||||||
|
Issuance of common stock subject to exercise of stock options
|
10,026 | 7,235 | ||||||
|
Excess tax benefits from stock-based compensation
|
2,200 | 1,700 | ||||||
|
Principal payments on long-term indebtedness and line of credit
|
(15,494 | ) | (33,291 | ) | ||||
|
Contingent value right payment
|
(10,000 | ) | - | |||||
|
Restricted cash deposit
|
(3 | ) | (2 | ) | ||||
|
Net cash provided by (used in) financing activities
|
14,251 | (9,358 | ) | |||||
|
Effect of exchange rate changes on cash and cash equivalents
|
1 | (21 | ) | |||||
|
Net increase (decrease) in cash and cash equivalents
|
(25,118 | ) | 66,095 | |||||
|
Cash and cash equivalents at beginning of period
|
169,019 | 102,924 | ||||||
|
Cash and cash equivalents at end of period
|
$ | 143,901 | $ | 169,019 | ||||